{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Pancreatic+Neoplasm&page=7", "query": { "condition": "Malignant Pancreatic Neoplasm", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 213, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Pancreatic+Neoplasm&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Pancreatic+Neoplasm&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T23:30:05.084Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04267575", "title": "Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Malignant Solid Neoplasm", "Stage IV Breast Cancer", "Stage IV Prostate Cancer", "Stage IV Pancreatic Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Colon Cancer", "Stage IV Colorectal Cancer", "Stage IV Liver Cancer", "Stage IV Renal Cell Cancer", "Stage IV Rectal Cancer", "Stage IV Lung Cancer", "Stage IV Small Intestinal Cancer", "Stage IV Gastric Cancer", "Stage IV Bladder Cancer" ], "interventions": [ { "name": "Canady Helios Cold Plasma Scalpel", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Jerome Canady, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-07-30", "completion_date": "2023-04-14", "has_results": true, "last_update_posted_date": "2021-08-09", "last_synced_at": "2026-10-12T23:30:05.084Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04267575" }, { "nct_id": "NCT07285044", "title": "The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyloidosis", "Basal Cell Carcinoma", "Biliary Tract Carcinoma", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Fallopian Tube Carcinoma", "Gastroesophageal Junction Carcinoma", "Glioblastoma", "Head and Neck Carcinoma", "Hematopoietic and Lymphatic System Neoplasm", "Hepatocellular Carcinoma", "Hodgkin Lymphoma", "Lung Carcinoma", "Malignant Solid Neoplasm", "Mantle Cell Lymphoma", "Melanoma", "Merkel Cell Carcinoma", "Multiple Myeloma", "Myelodysplastic Syndrome", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Primary Peritoneal Carcinoma", "Prostate Carcinoma", "Renal Cell Carcinoma", "Squamous Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "Cancer Therapeutic Procedure", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-12-18", "completion_date": "2027-05-15", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-12T23:30:05.084Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07285044" }, { "nct_id": "NCT07118176", "title": "Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anal Carcinoma", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Cholangiocarcinoma", "Colorectal Carcinoma", "Esophageal Carcinoma", "Gastric Carcinoma", "Head and Neck Carcinoma", "Hematopoietic and Lymphatic System Neoplasm", "Hepatocellular Carcinoma", "Lung Carcinoma", "Malignant Adrenal Gland Neoplasm", "Malignant Brain Neoplasm", "Malignant Neoplasm of Unknown Primary", "Malignant Solid Neoplasm", "Malignant Testicular Neoplasm", "Malignant Uterine Neoplasm", "Neuroendocrine Neoplasm", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Penile Carcinoma", "Pleural Carcinomatosis", "Primary Peritoneal Carcinoma", "Prostate Carcinoma", "Salivary Gland Carcinoma", "Sarcoma", "Skin Carcinoma", "Solitary Fibrous Tumor", "Thymus Carcinoma", "Thyroid Gland Carcinoma", "Thyroid Gland Medullary Carcinoma", "Urothelial Carcinoma", "Vaginal Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Gallium Ga 68 FAPi-46", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-08-01", "completion_date": "2027-09-07", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-12T23:30:05.084Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07118176" }, { "nct_id": "NCT00909558", "title": "Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Glioma", "Hepatocellular Cancer", "Squamous Cell Lung Cancer", "Pancreatic Cancer", "Colon Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Autologous Natural Killer / Natural Killer T Cell Immunotherapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Envita Medical Center, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 24, "start_date": "2009-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-02-24", "last_synced_at": "2026-10-12T23:30:05.084Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00909558" }, { "nct_id": "NCT06835569", "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "PDAC - Pancreatic Ductal Adenocarcinoma", "NSCLC (Non-small Cell Lung Cancer)", "CRC (Colorectal Cancer)", "Advanced Solid Tumors" ], "interventions": [ { "name": "ALTA3263", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed + Cisplatin /Carboplatin", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "GnP", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alterome Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2025-03-05", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-12T23:30:05.084Z", "location_count": 12, "location_summary": "Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06835569" }, { "nct_id": "NCT05563272", "title": "89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gastric Cancer", "Glioblastoma Multiforme", "Cholangiocarcinoma", "Hepatocellular Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Nasopharyngeal Carcinoma", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer", "Epithelial Ovarian Cancer", "Pancreatic Ductal Adenocarcinoma", "Soft Tissue Sarcoma", "Gastric Adenocarcinoma", "Malignant Mesothelioma (MM)", "Von Hippel Lindau", "Bladder Cancer", "Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "89Zr-girentuximab for PET/CT imaging of CAIX positive tumors", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Telix Pharmaceuticals (Innovations) Pty Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 11, "start_date": "2023-06-06", "completion_date": "2025-05-09", "has_results": false, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-10-12T23:30:05.084Z", "location_count": 10, "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Traverse City", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05563272" }, { "nct_id": "NCT03168737", "title": "18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Breast Neoplasm", "Malignant Colorectal Neoplasm", "Malignant Pancreatic Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorine F 18-fluoroazomycin Arabinoside", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2017-09-22", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-12T23:30:05.084Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03168737" }, { "nct_id": "NCT02309632", "title": "Pancreatic Cancer Screening of High-Risk Individuals in Arkansas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Neoplasms", "Peutz-Jegher's Syndrome", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Ataxia Telangiectasia", "Familial Atypical Mole-Malignant Melanoma Syndrome", "Colorectal Neoplasms, Hereditary Nonpolyposis", "Hereditary Pancreatitis" ], "interventions": [ { "name": "Pancreatic Cancer Screening Pathway 1", "type": "OTHER" }, { "name": "Pancreatic Cancer Screening Pathway 2", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2015-11", "completion_date": "2019-07-19", "has_results": false, "last_update_posted_date": "2019-07-29", "last_synced_at": "2026-10-12T23:30:05.084Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02309632" }, { "nct_id": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Anatomic Stage IV Breast Cancer AJCC v8", "Anemia", "Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Castration-Resistant Prostate Carcinoma", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hematopoietic and Lymphoid System Neoplasm", "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Breast Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Primary Myelofibrosis", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Hematologic Malignancy", "Recurrent Hodgkin Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelodysplastic/Myeloproliferative Neoplasm", "Recurrent Myeloproliferative Neoplasm", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Hematologic Malignancy", "Refractory Hodgkin Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Myelodysplastic Syndrome", "Refractory Myelodysplastic/Myeloproliferative Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Refractory Primary Myelofibrosis", "Refractory Small Lymphocytic Lymphoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dacomitinib", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Panobinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Tretinoin", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 2, "start_date": "2020-04-01", "completion_date": "2020-12-10", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-10-12T23:30:05.084Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03878524" }, { "nct_id": "NCT04870034", "title": "Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Colorectal Carcinoma", "Lung Adenocarcinoma", "Malignant Solid Neoplasm", "Pancreatic Carcinoma" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-01-15", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2023-12-22", "last_synced_at": "2026-10-12T23:30:05.084Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04870034" } ] }